Using the Chinese Indigenization FS Scale in the Diagnosis of Fibromyalgia: Specificity and Sensitivity in Clinical Practice
1 other identifier
observational
59
1 country
1
Brief Summary
This study aimed to evaluate the specificity and sensitivity of the diagnostic criteria for fibromyalgia after conducting local validation in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 21, 2024
CompletedFirst Submitted
Initial submission to the registry
July 8, 2024
CompletedFirst Posted
Study publicly available on registry
August 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2025
CompletedOctober 21, 2024
October 1, 2024
10 months
July 8, 2024
October 17, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Diagnosis of fibromyalgia with the Polysymptomatic Distress Scale(PDS)
The PDS scale fibromyalgia severity (FS) scale also known as the fibromyalgia severity (FS) scale. It is the sum of the WPI and SSS, and ranges is from 0-31 with higher score indicating more severity.
up to 1 week
Secondary Outcomes (6)
QOL as measured by Short Form-36 Health Status Questionnaire(SF-36)
up to 1 week
Fibromyalgia symptoms severity as measured by the Rebised Fibromyalgia Impact Questionnaire(FIQR)
up to 1 week
Depression scores as measured by Beck depression inventory(BDI)
up to 1 week
Stress scores as measured by Perceived Stress Scale(PSS)
up to 1 week
Sleep scores as measured by Pittsburgh sleep quality index(PSQI)
up to 1 week
- +1 more secondary outcomes
Study Arms (2)
chronic widespread pain
Fibromyalgia
Interventions
The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
Eligibility Criteria
chronic widespread pain: pain on the left side of the body, pain on the right side, pain above the waist, and pain below the waist. In addition, axial bone pain (cervical or anterior chest or thoracic or lower back pain) must be present. In this definition, shoulder and hip pain are considered pain on each affected side. "Lower back pain" is thought to be lower pain.)
You may qualify if:
- At least 18 years of age; Patients with chronic widespread pain; Able to complete the questionnaire.
You may not qualify if:
- Terminal patients with severe psychiatric diseases, tumors, systemic lupus erythematosus, systemic sclerosis, or other serious diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Guang'anmen Hospital of China Academy of Chinese Medical Scienceslead
- Hebei Provincial Hospital of Traditional Chinese Medicinecollaborator
- BAODING NO.1 HOSPITAL OF TCMcollaborator
- Inner Mongolia Hospital of Traditional Chinese Medicinecollaborator
- Shenzhen Hospital of Traditional Chinese Medicinecollaborator
- Suzhou Hospital of Traditional Chinese Medicinecollaborator
Study Sites (1)
Guang'anmen Hospital
Beijing, Beijing Municipality, 100053, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
July 8, 2024
First Posted
August 1, 2024
Study Start
May 21, 2024
Primary Completion
March 31, 2025
Study Completion
May 31, 2025
Last Updated
October 21, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share